BlackRock, Inc. Increases Stake in Myriad Genetics, Inc. to 8.5%

BlackRock, Inc. has filed an amended Schedule 13G (Amendment No. 5) with the SEC, reporting a significant increase in its stake in Myriad Genetics, Inc. (MYGN). As of March 31, 2026, BlackRock beneficially owns 7,976,163 shares of common stock, representing an 8.5% ownership interest in the company. This is a notable increase from the previously reported 0.0% position, indicating a substantial acquisition of shares. Of the total shares held, BlackRock has sole voting power over 7,841,058 shares and sole dispositive power over all 7,976,163 shares. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Various subsidiaries of BlackRock are identified as having ownership interests, though no single entity's interest exceeds 5%. The filing was signed by Spencer Fleming, Managing Director, on April 7, 2026.